Methylprednisolone

# Methylprednisolone ## Overview - **Classification**: Corticosteroid, Glucocorticoid - **Mechanism**: Potent anti-inflammatory and immunosuppressive effects by binding to glucocorticoid receptors, inhibiting pro-inflammatory mediators. ## Primary Indications 1. **Inflammatory & Allergic Conditions**: Acute asthma exacerbation, severe allergic reactions, rheumatoid arthritis. 2. **Autoimmune Disorders**: Systemic lupus erythematosus, multiple sclerosis exacerbations. 3. **Organ Transplant**: Prevention and treatment of transplant rejection. 4. **Oncologic Conditions**: Adjunctive therapy for some leukemias and lymphomas. ## Adult Dosing ### Standard Dosing **Acute Asthma/COPD Exacerbation** - **Dose**: **40-80 mg** - **Frequency**: Once daily or in 2 divided doses - **Route**: PO or IV - **Duration**: Typically **3-10 days** **Severe Allergic Reactions / Anti-inflammatory** - **Dose**: **20-80 mg** - **Frequency**: Once daily - **Route**: PO or IV - **Duration**: Tailored to condition, often tapered **Multiple Sclerosis Exacerbation (Pulse Therapy)** - **Dose**: **500 mg to 1 g** - **Frequency**: Once daily - **Route**: IV - **Duration**: **3-5 days** ### Dose Adjustments - **Renal Impairment**: No specific dose adjustment needed. Metabolized hepatically. - **Hepatic Impairment**: No specific dose adjustment recommended. Use with caution in severe cases. - **Elderly Patients**: Monitor for increased risk of adverse effects (osteoporosis, hyperglycemia). Start lower doses if frail. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Use limited; consult specialist. E.g., for BPD prevention: **0.1-0.2 mg/kg/dose** - **Frequency**: Q12-24 hours - **Maximum**: **0.4 mg/kg/day** - **Special Notes**: Risk of neurodevelopmental impairment. Taper slowly. ### Infants (1-12 months) - **Dose**: **0.5-1.5 mg/kg/day** - **Frequency**: Once daily or divided Q6-12 hours - **Maximum**: **60 mg/day** (or adult dose for specific indications) - **Special Notes**: Monitor growth, blood pressure, and bone density. ### Children (1-12 years) - **Dose**: **0.5-2 mg/kg/day** for anti-inflammatory/immunosuppression - **Frequency**: Once daily or divided Q6-12 hours - **Maximum**: **60-80 mg/day** (or adult dose, e.g., for pulse therapy) - **Special Notes**: Tapering required for courses > 5-7 days. Consider alternate-day therapy for chronic use. ### Adolescents (13-18 years) - **Dose**: Generally follows adult dosing guidelines. - **Maximum**: Adult maximum doses. - **Special Notes**: Ensure full linear growth before long-term use. ## Safety Information ### Contraindications - **Absolute**: Systemic fungal infections - **Absolute**: Known hypersensitivity to methylprednisolone or components - **Relative**: Live or live attenuated vaccines when immunosuppressed ### Common Adverse Effects - **Very Common (>10%)**: Hyperglycemia, hypertension, insomnia, mood changes, increased appetite - **Common (1-10%)**: Fluid retention, dyspepsia, adrenal suppression (with prolonged use), osteoporosis (long-term), skin thinning - **Serious but Rare**: GI perforation, avascular necrosis, psychiatric disturbances, glaucoma/cataracts, severe infections ### Key Drug Interactions - **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir)**: Increased methylprednisolone levels; monitor for toxicity. - **CYP3A4 Inducers (e.g., rifampin, phenytoin)**: Decreased methylprednisolone levels; monitor for reduced efficacy. - **NSAIDs**: Increased risk of GI ulceration and bleeding. - **Warfarin**: May alter anticoagulant effect; monitor INR closely. - **Diuretics (loop/thiazide)**: Increased risk of hypokalemia. ## Monitoring & Follow-up - **Before Treatment**: Baseline weight, blood pressure, blood glucose, electrolytes, bone mineral density (for long-term). - **During Treatment**: Blood glucose (especially in diabetics), blood pressure, electrolytes, weight, signs of infection (frequency depends on duration/dose). - **Clinical Signs**: Watch for mood changes, edema, GI upset, signs of infection, vision changes. ## Clinical Pearls - 💡 **Tapering**: For courses > 7-10 days, gradually taper the dose to prevent adrenal insufficiency. - 💡 **Timing**: Administer oral doses in the morning to mimic natural cortisol rhythm and minimize insomnia. - 💡 **GI Protection**: Consider a PPI or H2RA for patients at high risk of GI upset, especially with concomitant NSAIDs. - 💡 **Immunosuppression**: Counsel patients on increased infection risk and to report fever/symptoms promptly. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.